+44 20 8123 2220
info@marketpublishers.com

Ankylosing Spondylitis - Pipeline Insight, 2021

https://marketpublishers.com/r/A7B72EDE39EEN.html
Date: May 2021
Pages: 80
Price: US$ 2,000.00 (Single User License)
ID: A7B72EDE39EEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Ankylosing Spondylitis - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Ankylosing Spondylitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ankylosing Spondylitis Understanding

Ankylosing Spondylitis: Overview

Ankylosing Spondylitis (AS) is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints (Vertebrae) that can lead to chronic pain and discomfort. Ankylosing Spondylitis also cause pain, inflammation in other parts of the body such as the shoulders, hips, ribs , heels and small joints of the hands and feet. In some cases, the eyes are also involved (known as iritis or uveitis). In more advanced cases, these inflammation can lead to new bone formation in the spine, causing sections of spine top fuse in fixed, immobile position. The hallmark feature of Ankylosing spondylitis is the involvement of sacroiliac (SI) joints during the progression of disease. Ankylosing Spondylitis (AS) symptoms occurs at any age, but they start occurring at the age of 45. It also affect children, called juvenile ankylosing spondylitis, and more

commonly occur in boys than in girls.

'Ankylosing Spondylitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ankylosing Spondylitis pipeline landscape is provided which includes the disease overview and Ankylosing Spondylitis treatment guidelines. The assessment part of the report embraces, in depth Ankylosing Spondylitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ankylosing Spondylitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D. The therapies under development are focused on novel approaches to treat/improve Ankylosing Spondylitis.

Ankylosing Spondylitis Emerging Drugs Chapters

This segment of the Ankylosing Spondylitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ankylosing Spondylitis Emerging Drugs

Tofacitinib: Pfizer

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The drug is in preregistration stage for the

treatment of Ankylosing spondylitis.

Bimekizumab: UCB

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralizes IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. The drug is in phase 3 development stage for the treatment of Ankylosing spondylitis.

Namilumab: Izana Bioscience

Namilumab (IZN-101) is a monoclonal antibody therapy targeting granulocyte macrophagecolony stimulating factor (GM-CSF). IZN-101 is also in development for the treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), a debilitating arthritic disease with no cure. The antibody has demonstrated efficacy and safety in a phase IIb trial conducted in over 100 rheumatoid arthritis patients, and a phase II proof-of-concept study in ankylosing spondylitis is ongoing.

KIN-1901: Kinevant Sciences

KIN-1901 is a fully human immunoglobulin monoclonal antibody (mAb) directed towards a proinflammatory cytokine that is believed to have a role in inflammation and autoimmunity, and is found in synovial fluid from patients with spondyloarthritis. Therefore, neutralization of this cytokine activity by specific monoclonal antibodies (mAbs) could be beneficial in treating certain spondyloarthropathies such as ankylosing spondylitis (AS). The drug is in phase 1 of development stage for the treatment of Ankylosing spondylitis.

AK111: Akeso Biopharma

AK111 is a humanized IL-17 monoclonal antibody intended for the treatment of psoriasis, ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA). It is being developed by Akeso Biopharma.

+44 20 8123 2220
info@marketpublishers.com

Further product details are provided in the repor

Ankylosing Spondylitis: Therapeutic Assessment

This segment of the report provides insights about the different Ankylosing Spondylitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ankylosing Spondylitis

There are approx. 30+ key companies which are developing the therapies for Ankylosing Spondylitis. The companies which have their Ankylosing Spondylitis drug candidates in the most advanced stage, i.e. preregistration include, Pfizer.

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Subcutaneous

Intravenous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Small molecule

Recombinant fusion proteins

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ankylosing Spondylitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ankylosing Spondylitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ankylosing Spondylitis drugs.

+44 20 8123 2220
info@marketpublishers.com

Ankylosing Spondylitis Report Insights

- Ankylosing Spondylitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs

Ankylosing Spondylitis Report Assessment

- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Ankylosing Spondylitis drugs?
- How many Ankylosing Spondylitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ankylosing Spondylitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ankylosing Spondylitis therapeutics?

+44 20 8123 2220
info@marketpublishers.com

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ankylosing Spondylitis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Pfizer

Amgen

Sun Pharma Global

Jiangsu Hengrui Medicine Co.

Izana Bioscience

Suzhou Zelgen

Iltoo Pharma

Akeso Biopharma

Kinevant Sciences

Qyuns Therapeutics

Enzene Biosciences

Xbrane Biopharma

Dice molecules

Mycenax Biotech

+44 20 8123 2220
info@marketpublishers.com

Nimbus Therapeutics

Key Products

Tofacitinib

Apremilast

Tildrakizumab

SHR0302

Namilumab

Jaktinib

AK111

KIN-1901

QX002N

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Executive Summary
Ankylosing Spondylitis: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Ankylosing Spondylitis – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
  Ankylosing Spondylitis companies' collaborations, Licensing, Acquisition -Deal Value Trends
Ankylosing Spondylitis Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
  Comparative Analysis
Tofacitinib: Pfizer
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Namilumab: Izana Bioscience
  Product Description
  Research and Development
  Product Development Activities

+44 20 8123 2220
info@marketpublishers.com

Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
KIN-1901: Kinevant Sciences
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Ankylosing Spondylitis Key Companies
Ankylosing Spondylitis Key Products
Ankylosing Spondylitis- Unmet Needs
Ankylosing Spondylitis- Market Drivers and Barriers
Ankylosing Spondylitis- Future Perspectives and Conclusion
Ankylosing Spondylitis Analyst Views
Ankylosing Spondylitis Key Companies
Appendix

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1 Total Products for Ankylosing Spondylitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Ankylosing Spondylitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Ankylosing Spondylitis - Pipeline Insight, 2021
Product link: https://marketpublishers.com/r/A7B72EDE39EEN.html
Price: US$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A7B72EDE39EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970